ArticleTransplantation2026
Kinetics and Clinical Outcomes of EBV DNAemia in Whole Blood and Plasma Among Pediatric Liver Transplant Recipients: A Single-center Experience.
Article in Transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundData on the course of Epstein-Barr virus (EBV) DNAemia are limited in the pediatric liver transplant (LT) setting. This study aims to analyze the kinetics and clinical outcomes of EBV DNAemia in whole blood (WB) and plasma, and to evaluate the incidence and risk factors for EBV DNAemia, chronic high EBV load (CHL) carriage, and posttransplant lymphoproliferative disorder (PTLD).
methodsA retrospective analysis of longitudinal EBV DNAemia and clinical data from 237 children undergoing LT between April 2014 and May 2022 was performed. EBV DNAemia was measured in WB, switching to plasma on September 1, 2018. There was a 20-mo transitional period, during which both matrices were used.
resultsCHL occurred in 23 (22.1%) patients monitored in WB. Peak EBV DNAemia and EBV DNAemia exposure (measured as the area under the concentration-time curve) >1 y post-LT were higher in PTLD cases, regardless of the matrix used. Among CHL carriers, 21.7% (5/23) developed PTLD. In age-adjusted analyses, cytomegalovirus (CMV) DNAemia within 1 y post-LT was associated with EBV DNAemia (relative risk [RR], 1.16; P = 0.026). CHL carriage was associated with CMV DNAemia within 1 y post-LT (RR, 2.33; P = 0.044), EBV donor-positive/recipient-negative (D+/R-: RR, 3.62; P = 0.036), ABO-incompatible graft (RR, 3.03; P < 0.001), and early EBV DNAemia (<6 mo: RR, 3.46; P = 0.030). PTLD development was associated with early EBV DNAemia (<6 mo: RR, 3.58; P = 0.022) and CMV D+/R- (RR, 2.49; P = 0.030).
conclusionsThe study provides longitudinal data on EBV DNAemia in the context of CHL and PTLD. Prospective studies are warranted to validate the identified factors associated with EBV-related outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.